Plasma Membrane Ca2+ ATPase Isoform 4b Binds to Membrane-associated Guanylate Kinase (MAGUK) Proteins via Their PDZ (PSD-95/Dlg/ZO-1) Domains*

Eunjoon KimDagger §, Steven J. DeMarco, Shirin M. Marfatiapar , Athar H. Chishtipar **, Morgan ShengDagger Dagger Dagger , and Emanuel E. Strehler§§

From the Dagger  Howard Hughes Medical Institute and Department of Neurobiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, the  Program in Molecular Neuroscience, Department of Biochemistry and Molecular Biology, Mayo Clinic/Foundation, Rochester, Minnesota 55905, and the par  Laboratory of Tumor Cell Biology, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02135

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Plasma membrane Ca2+ ATPases are P-type pumps important for intracellular Ca2+ homeostasis. The extreme C termini of alternatively spliced "b"-type Ca2+ pump isoforms resemble those of K+ channels and N-methyl-D-aspartate receptor subunits that interact with channel-clustering proteins of the membrane-associated guanylate kinase (MAGUK) family via PDZ domains. Yeast two-hybrid assays demonstrated strong interaction of Ca2+ pump 4b with the PDZ1+2 domains of several mammalian MAGUKs. Pump 4b and PSD-95 could be co-immunoprecipitated from COS-7 cells overexpressing these proteins. Surface plasmon resonance revealed that a C-terminal pump 4b peptide interacted with the PDZ1+2 domains of hDlg with nanomolar affinity (KD = 1.6 nM), whereas binding to PDZ3 was in the micromolar range (KD = 1.2 µM). In contrast, the corresponding C-terminal peptide of Ca2+ pump 2b interacted weakly with PDZ1+2 and not at all with PDZ3 of hDlg. Ca2+ pump 4b bound strongly to PDZ1+2+3 of hDlg on filter assays, whereas isoform 2b bound weakly, and the splice variants 2a and 4a failed to bind. Together, these data demonstrate a direct physical binding of Ca2+ pump isoform 4b to MAGUKs via their PDZ domains and reveal a novel role of alternative splicing within the family of plasma membrane Ca2+ pumps. Alternative splicing may dictate their specific interaction with PDZ domain-containing proteins, potentially influencing their localization and incorporation into functional multiprotein complexes at the plasma membrane.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Temporal and spatial control of intracellular Ca2+ concentrations is essential for eukaryotic cell physiology. Plasma membrane Ca2+ ATPases (PMCAs)1 represent a ubiquitous, high affinity system for the expulsion of Ca2+ from the cell and are thought to be responsible for the long-term setting and maintenance of intracellular Ca2+ levels (1, 2). Mammalian PMCAs are encoded by a multigene family consisting of four members termed PMCA 1-4 (3). Additional isoform diversity is generated via alternative RNA splicing (3, 4). Alternative splicing of the C-terminal tail has been shown to alter the regulatory properties of PMCA isoforms, particularly with respect to phosphorylation and calmodulin stimulation (5-10). Many PMCA isoforms and splice variants are expressed in a tissue- and cell type-specific manner (11-17), and in several cell types, the PMCA has been shown to be concentrated in specific membrane domains by immunocytochemical analyses. For example, in kidney and intestinal epithelia involved in transcellular Ca2+ flux, the pump is generally localized to the basolateral membrane (18). Using immunoelectron microscopy, the PMCA was recently detected at the plasma membrane surrounding the soma, as well as in the dendrites and spines of cerebellar Purkinje cells where it co-localized with P-type Ca2+ channels (19). Taken together, these studies indicate that different isoforms of the PMCA may play an active role in the local control of Ca2+ signaling and the dynamic regulation of Ca2+ microdomains (7, 20). However, the mechanisms by which PMCA isoforms are localized to specific regions of the plasma membrane are unknown.

Recent studies have shown that several membrane receptors and channels are clustered into multiprotein complexes linked to the cytoskeleton via interactions of their C-terminal cytosolic tails with a novel protein interaction module called the PDZ domain (21-24). PDZ domains were first recognized in the post-synaptic density protein PSD-95/SAP90 (25). They are also present in the Drosophila discs-large (Dlg) tumor suppressor protein and the zona occludens ZO-1 tight junctional protein (hence the name PDZ) and have since been demonstrated in a large variety of multifunctional proteins (21, 24, 26-28) where they act as mediators of protein-protein interactions. Several of these PDZ domain-containing proteins, including PSD-95, Chapsyn-110, and hDlg (29-31), are members of the membrane-associated guanylate kinase (MAGUK) protein family (32). A short, consensus C-terminal sequence motif (-E(T/S)XV*, where * represents the stop codon) has been shown to be critical for the interaction between membrane proteins (such as Shaker-type K+ channels and NMDA receptor NR2 subunits) and the PDZ domains present in the PSD-95 family of MAGUKs (24, 29, 33-35).

In the PMCAs, the C-terminal sequence of all "b" type alternative splice variants contains the consensus -ETSL* or -ETSV* which is similar to the -E(T/S)XV* motif found in Shaker K+ channel and NR2 NMDA receptor proteins. Human PMCA1b, -2b, and -3b end with the sequence -ETSL*, whereas hPMCA4b ends with the sequence -ETSV* (3). Based on this observation, we reasoned that the intracellular C-terminal tail of hPMCA4b may interact with MAGUKs via their PDZ domains. To test this hypothesis, we analyzed the interaction of hPMCA4b with the PDZ domains of several MAGUKs using a variety of binding assays. The results documented in this paper provide the first evidence of direct binding of the PMCA4b isoform to MAGUKs and suggest a novel mechanism by which alternative splicing generates Ca2+ pump isoforms that may be differentially recruited to multifunctional protein complexes involved in Ca2+ regulation.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Plasmid Constructs-- A cDNA fragment encoding the C-terminal 71 residues (amino acids 1135 to 1205) of hPMCA4b was cloned into pBHA (LexA fusion vector) and used in yeast two-hybrid assays with various PDZ domain constructs made in pGAD10 (CLONTECH, Palo Alto, CA). The pGAD10 constructs encoding each individual PDZ domain, or PDZ1+2 of PSD-95 fused to the GAL4 activation domain have been described (29), as has the construct encoding all three PDZ domains of hDlg (clone 4 (29)). pGAD10 plasmids carrying the corresponding domains of rat Chapsyn-110 (30) were similarly constructed by PCR amplification of the desired cDNA fragments followed by subcloning into pGAD10 (PDZ1, aa 77-193; PDZ2, aa 187-300; PDZ3, aa 418-503; PDZ1+2, aa 77-300). pGEX-2T constructs expressing the PDZ1+2 domains (aa 216-413) and the PDZ3 domain (aa 457-552) of hDlg as glutathione S-transferase (GST) fusion proteins and the pRSETA vector encoding PDZ1+2+3 of hDlg with an N-terminal His-tag have been described (36, 37). Constructs expressing the C-terminal sequences of hPMCA2a (aa 1126-1168), -2b (aa 1141-1212), -4a (aa 1115-1170), and -4b (aa 1135-1205) as GST fusion proteins with a protein kinase A phosphorylation site were made by PCR amplification of the appropriate cDNA fragments and subcloning them in-frame into pGEX-2TK (Pharmacia). The mammalian expression vectors for full-length hPMCA4b and PSD-95 have been described (29, 38).

Synthetic Peptides-- Peptides CT2b and CT4b corresponding to the C-terminal 10 residues of hPMCA2b (SPIHSLETSL) and hPMCA4b (SSLQSLETSV), respectively, were chemically synthesized in the Mayo Clinic Core Facility and were N-terminally coupled to biotin via a spacer sequence SGSG. The peptides were purified by high pressure liquid chromatography, and their purity was assessed by mass spectrometry.

Recombinant Protein Expression-- The PDZ1+2 and PDZ3 domains of hDlg and the C-terminal domains of PMCAs were expressed in E. coli as recombinant GST fusion proteins and purified using glutathione-Sepharose 4B as recommended by the manufacturer (Pharmacia). Purified proteins were dialyzed against HBS buffer (10 mM Hepes, pH 7.6, 150 mM NaCl, 3.5 mM EDTA, and 0.005% surfactant P20). The His-tagged hDlg PDZ1+2+3 protein was expressed in E. coli BL-21(DE3) and purified by metal chelate chromatography using a Poros MC20 column (Boehringer Mannheim).

Yeast Two-hybrid Analysis-- Two-hybrid interaction assays were performed as described (29) using yeast strain L40 harboring HIS3 and beta -Gal reporter genes under the control of LexA binding sites. Semiquantitative analysis based on the degree of reporter gene activation was carried out as described (29).

Cell Transfections, Immunoprecipitation, and Immunoblotting-- COS-7 cells grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 50 µg/ml gentamycin were transfected at 50% confluence by the LipofectAMINE method (Life Technologies, Inc.) as described (39, 40). Two days after transfection, cells were extracted in a 50-fold volume of Tris-buffered saline (pH 7.4) containing 1% Triton X-100 at 4 °C for 1 h. After centrifugation at 16,000 × g for 30 min, the supernatant was incubated with affinity-purified primary antibodies at 4 °C for 1 h. Immunoprecipitates were collected with protein A-Sepharose, separated on a 6% SDS-polyacrylamide gel, and analyzed by immunoblotting. A polyclonal guinea pig antibody against PSD-95 (29) and a monoclonal mouse antibody (JA3) against hPMCA4b (17) were used for immunoprecipitations at 1 µg/ml and 1:1000 dilution, respectively.

Gel Overlays-- Aliquots of purified His-tagged hDlg-PDZ1+2+3 protein (1 µg each) were run on a 10% SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane using standard Western blotting techniques (41). GST-PMCA fusion proteins and GST alone (control) were expressed in E. coli JM101 from the appropriate pGEX-2TK vector and were phosphorylated while bound to glutathione-Sepharose beads using bovine heart muscle protein kinase A (Sigma) and [gamma -32P]ATP (3,000 Ci/mmol, Amersham) (42). The labeled fusion proteins were eluted from the washed beads in 50 mM Tris-HCl, pH 8.0, containing 10 mM reduced glutathione (Sigma) and were used to probe the nitrocellulose membranes essentially as described (42).

Surface Plasmon Resonance Measurements-- The interaction between the PDZ domains of hDlg and the C-terminal peptides of hPMCA2b and -4b was studied by surface plasmon resonance measurements using a BIAcore instrument (Biacore, Inc.) as described (36). 204 and 390 resonance units (RU), respectively, of biotinylated peptides CT2b and CT4b were captured on the streptavidin surface of a SA sensor chip (research grade). The purified recombinant proteins GST, GST-PDZ1+2, and GST-PDZ3 were exposed to the immobilized peptides at a concentration of 410 µg/ml. To quantify the affinity of the interaction of CT4b with PDZ1+2 of hDlg, 82 RU of peptide CT4b were immobilized on the SA sensor chip surface and increasing concentrations of GST-PDZ1+2 (ranging from 12.4 nM to 978 nM) were passed over the immobilized peptide surface. To quantify the interaction of CT4b with PDZ3 of hDlg, 394 RU of CT4b were captured on the surface of a SA sensor chip, and the immobilized peptide was exposed to increasing concentrations of GST-PDZ3 (0.83 µM to 65.2 µM).

    RESULTS AND DISCUSSION
Top
Abstract
Introduction
Procedures
Results & Discussion
References

The b splice forms of the human PMCAs terminate in the conserved sequence -S(L/V)ETS(L/V)* that matches the minimal -(T/S)XV* consensus motif for PDZ domain interaction (29, 33). The sequence -ETSV* of hPMCA4b matches the consensus precisely whereas that of all other PMCA b splice forms (-ETSL*) deviates conservatively from the consensus at the last residue. To test if hPMCA4b can interact with PDZ domains of known channel/receptor clustering molecules, we performed yeast two-hybrid assays using the C-terminal 71 residues of PMCA4b fused to the LexA DNA binding domain as "bait," and various PDZ domains fused to the GAL4 activating domain as potential partners. The interaction was assayed semiquantitatively based on the degree of HIS3 and beta -Gal reporter gene induction (29). Fig. 1 shows that no reporter gene activity was detected when the control plasmid pGAD10 was transformed into yeast expressing the LexA-PMCA4b fusion protein from the pBHA-PMCA bait construct. By contrast, both reporter genes were activated when the transformation was performed with the PDZ domain-expressing constructs. A very strong induction was observed when the combined PDZ1+2 domains of either PSD-95 or Chapsyn-110 or all three PDZ domains of hDlg were expressed together with the PMCA4b fusion protein (Fig. 1). As has been shown for the Kv1.4 potassium channel (29) and the NR2 subunits of NMDA receptors (33, 43), interaction of the PMCA4b C-terminal sequence was strongest with the individual PDZ domain 2 of the MAGUKs tested. However, an interaction with the PDZ1 and PDZ3 domains was also observed (Fig. 1). It is noteworthy that a weak but significant interaction was observed of the hPMCA4b with the PDZ3 domain of PSD-95 and Chapsyn-110. This is in contrast to the Kv1.4 potassium channel that showed no affinity for PDZ3 even in the sensitive two-hybrid assay (29). The crystal structures of the PDZ3 domain of hDlg alone and of PSD-95 complexed with a peptide ligand ending in the sequence -QTSV* were recently reported (34, 37), rationalizing the importance of the C-terminal Val and of the Thr residue at position -2. Because the extreme C termini of hPMCA4b (which can bind to PDZ3) and of Kv1.4 (which does not bind to PDZ3) differ only at position -1 (Ser in the PMCA, Asp in the Kv1.4), it is likely that the residue at this position (and/or additional more N-terminally located residues) also play a role in determining the binding affinity of a C-terminal peptide to the PDZ3 domain.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 1.   Interaction of hPMCA4b C-terminal domain with PDZ domains as determined by semiquantitative yeast two-hybrid assays. Top panel, schemes of the bait construct and the interacting MAGUKs. The bait consists of the LexA DNA binding domain (LexA DB) fused to residues 1135-1205 of hPMCA4b. The MAGUKs contain three PDZ domains, a Src Homology 3 (SH3) domain and a guanylate kinase-like domain (GUK). Bottom panel, the interaction of various test proteins (consisting of the Gal4 activation domain (Gal4 AD) fused to PDZ domains of various MAGUKs) with the PMCA bait was assayed semiquantitatively based on the degree of induction of the two reporter genes HIS3 and beta -Gal. HIS3 activity was determined by the percentage of yeast colonies growing on histidine-lacking medium: +++, >60%; ++, 30-60%; +, 10-30%; -, no significant growth. beta -Gal activity was estimated from the time taken for colonies to turn blue in 5-bromo-4-chloro-3-indolyl beta -D-galactoside filter lift assays at room temperature: +++, <45 min; ++, 45-90 min; +, 90-240 min; -, no significant activity.

To determine if hPMCA4b can interact with a PDZ domain protein when both are expressed as full-length proteins in a mammalian cell, COS-7 cells were transfected with expression vectors for hPMCA4b and PSD-95. Co-immunoprecipitation experiments were performed using either a polyclonal antibody against PSD-95 or a monoclonal antibody against PMCA4b. Both proteins were abundantly expressed upon transient transfection of COS-7 cells with the appropriate vectors (Fig. 2, lanes 1-3). PSD-95 and PMCA4b were effectively co-immunoprecipitated in reciprocal immunoprecipitation experiments using cells that had been co-transfected with the two expression plasmids (Fig. 2, lanes 4-7). Neither of the two antibodies showed nonspecific cross-reactivity with the partner protein as demonstrated by the inability of anti-PSD-95 to precipitate the PMCA from cells transfected with PMCA alone (Fig. 2, lane 5) and the inability of anti-PMCA4b to precipitate significant amounts of PSD-95 from cells expressing only PSD-95 (Fig. 2, lane 7, compare with lane 2). The small amount of PSD-95 immunoprecipitated by the anti-PMCA4b antibody from cells expressing PSD-95 (Fig. 2, lane 7) could be due to the presence of endogenously expressed PMCA4b in the COS-7 cells. However, under our immunoblotting conditions the endogenous PMCA4b remained below the detection limit (see Fig. 2, lanes 2 and 7). These data, therefore, show that full-length PMCA4b can interact with full-length PSD-95 in a cellular environment. Based on the yeast two-hybrid analysis, this interaction is likely mediated by binding of the C-terminal sequence of the pump to a PDZ domain (probably PDZ2) of its partner PDZ domain-containing protein (PSD-95/Chapsyn-110/hDlg).


View larger version (49K):
[in this window]
[in a new window]
 
Fig. 2.   Co-immunoprecipitation of hPMCA4b and PSD-95 from cotransfected COS cells. Extracts from COS-7 cells transfected with full-length hPMCA4b, PSD-95, or both together (as indicated on top of each lane) were either separated directly by SDS-PAGE (input, lanes 1-3) or immunoprecipitated (IP) with a polyclonal antibody against PSD-95 (PSD, lanes 4 and 5) or a monoclonal antibody against the PMCA4b (PMCA, lanes 6 and 7) prior to SDS-PAGE. The proteins were then analyzed by immunoblotting using the same antibodies as indicated on the right. The sizes of molecular mass standards are given in kDa, and their position is indicated on the left.

To quantify the interaction of the PMCA4b C terminus with the PDZ domains and to determine comparative values for a possible interaction of other PMCA b splice forms with the same PDZ domains, we performed surface plasmon resonance measurements using synthetic PMCA peptides and purified GST fusion proteins of the various PDZ domains of hDlg. When recombinant GST, GST-PDZ1+2, and GST-PDZ3 were exposed to the immobilized peptide CT4b (corresponding to the C-terminal 10 residues of hPMCA4b), both GST-PDZ1+2 and GST-PDZ3 fusion proteins bound to the peptide (Fig. 3A) whereas no binding was observed with GST alone. Interestingly, when the same experiment was performed with immobilized peptide CT2b (corresponding to the C-terminal 10 residues of hPMCA2b), binding was only evident to GST-PDZ1+2. No binding was observed with either GST-PDZ3 or GST alone (Fig. 3B). The affinity of the interaction of CT4b with the combined PDZ1+2 domains of hDlg was quantified by passing increasing concentrations of GST-PDZ1+2 fusion protein over the CT4b peptide surface (Fig. 3C). Analysis of the association and dissociation phases of the sensorgrams yielded an overall dissociation constant, KD, of 1.64 nM (ka = 1.16 × 106 M-1 s-1 and kd = 1.9 × 10-3 s-1), indicative of a high affinity interaction between CT4b and the combined PDZ1+2 domains of hDlg. The interaction between CT4b and PDZ3 of hDlg was similarly analyzed. A KD of 1.22 µM was calculated from the association (ka = 3.59 × 103 M-1 s-1) and dissociation (kd = 4.38 × 10-3 s-1) rate constants (Fig. 3D), indicating a relatively low affinity interaction between CT4b and the PDZ3 domain of hDlg. These results fully agree with the two-hybrid interaction data. The binding affinities measured for PDZ domains of hDlg should be broadly extrapolatable to PSD-95 and Chapsyn-110, since the equivalent PDZ domains of these closely related proteins are highly conserved and no differences in binding specificity between the different proteins have been detected to date (29, 43).2 Quantification of the interaction between peptide CT2b and PDZ1+2 of hDlg was not attempted due to the relatively low affinity of the interaction (compare Fig. 3, A and B) as well as technical difficulties in capturing sufficient amounts of the CT2b peptide on the biosensor chip surface.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 3.   Interaction between PMCA C-terminal peptides and PDZ domains of hDlg. A and B, peptides CT4b (A) and CT2b (B) were immobilized on the streptavidin chip and the binding of GST alone (GST), GST-PDZ1+2, and GST-PDZ3 was determined as described under "Experimental Procedures." C and D, the interaction kinetics between peptide CT4b and GST-PDZ1+2 (C) or GST-PDZ3 (D) were measured by passing increasing concentrations (indicated over each trace) of the recombinant fusion proteins over the immobilized peptides, followed by analysis of the association and dissociation rates using a BIAcore instrument (Pharmacia-Biacore, Inc.).

Independent confirmation of the specificity of the interaction of hPMCA4b with the PDZ domains of hDlg was obtained using a filter assay. Immobilized recombinant His-tagged hDlg-PDZ1+2+3 fusion protein was probed with radiolabeled GST alone or with various GST-PMCA C-terminal fusion proteins. As shown in Fig. 4, GST-hPMCA4b bound strongly to the hDlg-PDZ1+2+3 fusion protein, whereas GST-hPMCA2b bound weakly and GST-hPMCA2a, GST-hPMCA4a and GST alone did not bind at all. These findings agree with the BIAcore measurements showing a much reduced affinity of hPMCA2b for the PDZ1+2 domains of hDlg. Importantly, the results also show that none of the alternatively spliced "a" forms of the PMCA are able to bind the PDZ domains and thus suggest a novel mechanism whereby alternatively spliced forms of the Ca2+ pumps are distinguished by their interaction with PDZ domain-containing target proteins.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 4.   Specificity of the interaction of alternatively spliced hPMCA C termini with the PDZ domains of hDlg. Aliquots (1 µg) of recombinant His-tagged hDlg-PDZ1+2+3 were separated by SDS-PAGE and electroblotted onto nitrocellulose, and the filters were probed with 32P-labeled GST alone (GST) or with different GST-PMCA fusion proteins as indicated on top of each lane (see "Experimental Procedures").

The nanomolar affinity of hPMCA4b for the PDZ1+2 domains of hDlg suggests that hPMCA4b and hDlg may be binding partners in vivo where they are co-expressed in kidney and intestinal epithelial cells (17, 18, 29, 44-46) as well as in several regions of the brain (15, 29, 30, 47). An in vivo interaction between PMCA4b and other members of the PSD-95 family of MAGUKs may be equally plausible: PSD-95 and Chapsyn-110 have been found pre- and postsynaptically in several areas of the brain that also express PMCA4b (15, 30, 47). The large difference in binding affinity of the C termini of hPMCA4b and hPMCA2b to the PDZ1+2 domains of the PSD-95/Chapsyn-110/hDlg members of the MAGUK family underscores the importance of the carboxyl-terminal residue (Val in hPMCA4b, Leu in the other hPMCA b-splice forms) in determining the specificity of this interaction. This observation is consistent with the recently demonstrated target specificity of PDZ domains using an oriented peptide library approach (35). The selectivity and specificity of PDZ domain-target sequence interactions (27, 35, 48) also suggest that other PMCA isoforms of the b splice type, such as PMCA2b, may recognize novel PDZ domain-containing proteins.

An interaction of Ca2+ pump isoforms with specific PDZ domain proteins may be relevant for the local organization of Ca2+ signaling domains at the plasma membrane and/or for anchoring Ca2+ regulatory complexes to the cytoskeleton. It is probably not coincidental that the Ca2+ pump 4b can interact with the same clustering proteins (PSD-95, Chapsyn-110) as NMDA receptors. The ability of PSD-95 MAGUKs to homo- and heteromultimerize allows them to cocluster several different ligands (40) thus allowing for co-aggregation of Ca2+ pump and NMDA receptor proteins in the same membrane microdomain. The local concentration of Ca2+ pump (e.g. in dendritic spines) would facilitate the extrusion of calcium ions admitted into the dendritic spine through activated NMDA receptors, thereby restricting the duration of the Ca2+ signal. The functional significance of these interactions is currently under investigation.

    ACKNOWLEDGEMENTS

We thank E. Brittle for help with plasmid construction and fusion protein expression, A. Caride, A. G. Filoteo, and J. T. Penniston for antibody JA3, and B. J. Brown for help with Figs. 3 and 4.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grant CA 66263 (to A. H. C.) and the Mayo Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Present address: Dept. of Pharmacology, Pusan National University, Pusan 609-735, South Korea.

** Established investigator of the American Heart Association.

Dagger Dagger Assistant investigator of the Howard Hughes Medical Institute.

§§ To whom correspondence should be addressed. Tel.: 507-284-9372; Fax: 507-284-2384; E-mail: strehler.emanuel{at}mayo.edu.

1 The abbreviations used are: PMCA, plasma membrane calcium ATPase; aa, amino acids; GST, glutathione S-transferase; Dlg, Drosophila discs-large protein; hDlg, human homolog of Dlg; MAGUK, membrane-associated guanylate kinase; NMDA, N-methyl-D-aspartate; PDZ, PSD-95/Dlg/ZO-1; PSD-95, post-synaptic density protein of 95 kDa; RU, resonance units; PAGE, polyacrylamide gel electrophoresis; ZO-1, zona occludens protein-1; beta -Gal, beta -galactosidase.

2 E. Kim and M. Sheng, unpublished observations.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results & Discussion
References

  1. Carafoli, E. (1987) Annu. Rev. Biochem. 56, 395-433[CrossRef][Medline] [Order article via Infotrieve]
  2. Carafoli, E. (1991) Physiol. Rev. 71, 129-153[Free Full Text]
  3. Strehler, E. E. (1991) J. Membr. Biol. 120, 1-15[Medline] [Order article via Infotrieve]
  4. Carafoli, E., and Stauffer, T. (1994) J. Neurobiol. 25, 312-324[Medline] [Order article via Infotrieve]
  5. Enyedi, A., Filoteo, A. G., Gardos, G., and Penniston, J. T. (1991) J. Biol. Chem. 266, 8952-8956[Abstract/Free Full Text]
  6. Enyedi, A., Verma, A. K., Heim, R., Adamo, H. P., Filoteo, A. G., Strehler, E. E., Penniston, J. T. (1994) J. Biol. Chem. 269, 41-43[Abstract/Free Full Text]
  7. Monteith, G. R., and Roufogalis, B. D. (1995) Cell Calcium 18, 459-470[CrossRef][Medline] [Order article via Infotrieve]
  8. Verma, A. K., Enyedi, A., Filoteo, A. G., Strehler, E. E., Penniston, J. T. (1996) J. Biol. Chem. 271, 3714-3718[Abstract/Free Full Text]
  9. Seiz-Preiano, B. S., Guerini, D., and Carafoli, E. (1996) Biochemistry 35, 7946-7953[CrossRef][Medline] [Order article via Infotrieve]
  10. Enyedi, A., Verma, A. K., Filoteo, A. G., Penniston, J. T. (1996) J. Biol. Chem. 271, 32461-32467[Abstract/Free Full Text]
  11. Brandt, P., Neve, R. L., Kammesheidt, A., Rhoads, R. E., Vanaman, T. C. (1992) J. Biol. Chem. 267, 4376-4385[Abstract/Free Full Text]
  12. Stahl, W. L., Eakin, T. J., Owens, J. W., Jr., Breininger, J. F., Filuk, P. E., Anderson, W. R. (1992) Mol. Brain Res. 16, 223-231 [Medline] [Order article via Infotrieve]
  13. Stauffer, T. P., Hilfiker, H., Carafoli, E., and Strehler, E. E. (1993) J. Biol. Chem. 268, 25993-26003[Abstract/Free Full Text]; Correction (1994) J. Biol. Chem. 269, 32022
  14. Stauffer, T. P., Guerini, D., and Carafoli, E. (1995) J. Biol. Chem. 270, 12184-12190[Abstract/Free Full Text]
  15. Zacharias, D. A., Dalrymple, S. J., Strehler, E. E. (1995) Mol. Brain Res. 28, 263-272 [CrossRef][Medline] [Order article via Infotrieve]
  16. Stauffer, T. P., Guerini, D., Celio, M. R., Carafoli, E. (1997) Brain Res. 748, 21-29[CrossRef][Medline] [Order article via Infotrieve]
  17. Caride, A. J., Filoteo, A. G., Enyedi, A., Verma, A. K., Penniston, J. T. (1996) Biochem. J. 316, 353-359[Medline] [Order article via Infotrieve]
  18. Borke, J. L., Minami, J., Verma, A., Penniston, J. T., Kumar, R. (1987) J. Clin. Invest. 80, 1225-1231[Medline] [Order article via Infotrieve]
  19. Hillman, D. E., Chen, S., Bing, R., Penniston, J. T., Llinas, R. (1996) Neuroscience 72, 315-324[CrossRef][Medline] [Order article via Infotrieve]
  20. Brandt, P. C., and Vanaman, T. C. (1996) Glycobiology 6, 665-668[Medline] [Order article via Infotrieve]
  21. Sheng, M. (1996) Neuron 17, 575-578[Medline] [Order article via Infotrieve]
  22. Sheng, M., and Kim, E. (1996) Curr. Opin. Neurobiol. 6, 602-608[CrossRef][Medline] [Order article via Infotrieve]
  23. Fanning, A. S., and Anderson, J. M. (1996) Curr. Biol. 6, 1385-1388[Medline] [Order article via Infotrieve]
  24. Saras, J., and Heldin, C. H. (1996) Trends Biochem. Sci. 21, 455-458[CrossRef][Medline] [Order article via Infotrieve]
  25. Cho, K. O., Hunt, C. A., and Kennedy, M. B. (1992) Neuron 9, 929-942[Medline] [Order article via Infotrieve]
  26. Dong, H., O'Brien, R. J., Fung, E. T., Lanahan, A. A., Worley, P. F., Huganir, R. L. (1997) Nature 386, 279-284[CrossRef][Medline] [Order article via Infotrieve]
  27. Brakeman, P. R., Lanahan, A. A., O'Brien, R., Roche, K., Barnes, C. A., Huganir, R. L., Worley, P. F. (1997) Nature 386, 284-288[CrossRef][Medline] [Order article via Infotrieve]
  28. Tsunoda, S., Sierralta, J., Sun, Y., Bodner, R., Suzuki, E., Becker, A., Socolich, M., and Zuker, C. S. (1997) Nature 388, 243-249[CrossRef][Medline] [Order article via Infotrieve]
  29. Kim, E., Niethammer, M., Rothschild, A., Jan, Y. N., Sheng, M. (1995) Nature 378, 85-88[CrossRef][Medline] [Order article via Infotrieve]
  30. Kim, E., Cho, K. O., Rothschild, A., and Sheng, M. (1996) Neuron 17, 103-113[Medline] [Order article via Infotrieve]
  31. Lue, R. A., Marfatia, S. M., Branton, D., and Chishti, A. H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9818-9822[Abstract/Free Full Text]
  32. Kim, S. K. (1995) Curr. Opin. Cell Biol. 7, 641-649[CrossRef][Medline] [Order article via Infotrieve]
  33. Kornau, H. C., Schenker, L. T., Kennedy, M. B., Seeburg, P. H. (1995) Science 269, 1737-1740[Medline] [Order article via Infotrieve]
  34. Doyle, D. A., Lee, A., Lewis, J., Kim, E., Sheng, M., and MacKinnon, R. (1996) Cell 85, 1067-1076[Medline] [Order article via Infotrieve]
  35. Songyang, Z., Fanning, A. S., Fu, C., Xu, J., Marfatia, S. M., Chishti, A. H., Crompton, A., Chan, A. C., Anderson, J. M., Cantley, L. C. (1997) Science 275, 73-77[Abstract/Free Full Text]
  36. Marfatia, S. M., Cabral, J. H., Lin, L., Hough, C., Bryant, P. J., Stolz, L., Chishti, A. H. (1996) J. Cell Biol. 135, 753-766[Abstract]
  37. Cabral, J. H., Petosa, C., Sutcliffe, M. J., Raza, S., Byron, O., Poy, F., Marfatia, S. M., Chishti, A. H., Liddington, R. C. (1996) Nature 382, 649-652[CrossRef][Medline] [Order article via Infotrieve]
  38. Adamo, H. P., Verma, A. K., Sanders, M. A., Heim, R., Salisbury, J. L., Wieben, E. D., Penniston, J. T. (1992) Biochem. J. 285, 791-797[Medline] [Order article via Infotrieve]
  39. Kim, E., Naisbitt, S., Hsueh, Y. P., Rao, A., Rothschild, A., Craig, A. M., Sheng, M. (1997) J. Cell Biol. 136, 669-678[Abstract/Free Full Text]
  40. Hsueh, Y.-P., Kim, E., and Sheng, M. (1997) Neuron 18, 803-814[Medline] [Order article via Infotrieve]
  41. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (eds) (1996) Current Protocols in Molecular Biology, John Wiley and Sons, New York, NY
  42. Fischer, R., Wei, Y., and Berchtold, M. (1996) Biotechniques 21, 292-296[Medline] [Order article via Infotrieve]
  43. Niethammer, M., Kim, E., and Sheng, M. (1996) J. Neurosci. 16, 2157-2163[Abstract]
  44. Howard, A., Legon, S., and Walters, J. R. F. (1993) Am. J. Physiol. 265, G917-G925[Abstract/Free Full Text]
  45. Lue, R. A., Brandin, E., Chan, E. P., Branton, D. (1996) J. Cell Biol. 135, 1125-1137[Abstract]
  46. Matsumine, A., Ogai, A., Senda, T., Okumura, N., Satoh, K., Baeg, G.-H., Kawahara, T., Kobayashi, S., Okada, M., Toyoshima, K., and Akiyama, T. (1996) Science 272, 1020-1023[Abstract]
  47. Garner, C. C., and Kindler, S. (1996) Trends Cell Biol. 6, 429-433 [CrossRef][Medline] [Order article via Infotrieve]
  48. Stricker, N. L., Christopherson, K. S., Yi, B. A., Schatz, P. J., Raab, R. W., Dawes, G., Bassett, D. E., Jr., Bredt, D. S., Li, M. (1997) Nat. Biotechnol. 15, 336-342 [Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.